Cargando…

Effects of SGLT2 Inhibitors on Renal Outcomes in Patients With Chronic Kidney Disease: A Meta-Analysis

Introduction: The effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors on renal outcomes in patients with chronic kidney disease (CKD) were initially demonstrated in recent trials. However, the magnitude of renal benefits for CKD patients with different baseline features and underlying disea...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ning, Lv, Dan, Zhu, Xiangjun, Wei, Ping, Gui, Yuan, Liu, Shijia, Zhou, Enchao, Zheng, Min, Zhou, Dong, Zhang, Lu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591237/
https://www.ncbi.nlm.nih.gov/pubmed/34790672
http://dx.doi.org/10.3389/fmed.2021.728089
_version_ 1784599182687862784
author Li, Ning
Lv, Dan
Zhu, Xiangjun
Wei, Ping
Gui, Yuan
Liu, Shijia
Zhou, Enchao
Zheng, Min
Zhou, Dong
Zhang, Lu
author_facet Li, Ning
Lv, Dan
Zhu, Xiangjun
Wei, Ping
Gui, Yuan
Liu, Shijia
Zhou, Enchao
Zheng, Min
Zhou, Dong
Zhang, Lu
author_sort Li, Ning
collection PubMed
description Introduction: The effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors on renal outcomes in patients with chronic kidney disease (CKD) were initially demonstrated in recent trials. However, the magnitude of renal benefits for CKD patients with different baseline features and underlying diseases remains unclear. Method: We systematically searched the Embase, PubMed, Web of Science, and Cochrane library databases from inception to April 15, 2021 to identify eligible trials. The primary outcome was a composite of worsening kidney function, end-stage kidney disease (ESKD), or renal death. Efficacy and safety outcomes were stratified by baseline features, such as type 2 diabetes, heart failure, atherosclerotic cardiovascular disease, proteinuria, and renal function. Results: A total of nine studies were included. These studies included 25,749 patients with estimated glomerular filtration rate (eGFR)<60 mL/min/1.73 m(2) and 12,863 patients with urine albumin-to-creatinine ratio (UACR) >300 mg/g. SGLT2 inhibitors reduced the risk of the primary renal outcome by 30% in patients with eGFR<60 mL/min/1.73 m(2) (HR 0.70, [95% CI 0.58–0.83], I(2) = 0.00%) and by 43% in patients with UACR > 300 mg/g (HR 0.57, [95% CI 0.48–0.67], I(2) = 16.59%). A similar benefit was observed in CKD patients with type 2 diabetes. SGLT2 inhibitors had no clear effects on renal outcomes in patients with eGFR<60 mL/min/1.73 m(2) combined with atherosclerotic cardiovascular disease (HR 0.74, [95% CI 0.51–1.06], I(2) = 0.00%). However, they reduced the risk of major renal outcomes by 46% (HR 0.54, [95% CI 0.38–0.76], I(2) = 0.00%) in patients with atherosclerotic cardiovascular disease and macroalbuminuria (defined as UACR > 300 mg/g). SGLT2 inhibitors did not significantly reduce the risk of major renal outcomes in CKD patients with heart failure (eGFR<60 mL/min/1.73 m(2): HR 0.81, [95% CI 0.47–1.38], I(2) = 0.00%; UACR > 300 mg/g: HR 0.66, [95% CI 0.41–1.07], I(2) = 0.00%). SGLT2 inhibitors showed consistent renal benefits across different levels of eGFR (P interaction = 0.48). Conclusion: SGLT2 inhibitors significantly reduced the risk of the primary outcome in CKD patients. However, for patients with different features and underlying diseases, there exists differences in the renal protective effect.
format Online
Article
Text
id pubmed-8591237
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85912372021-11-16 Effects of SGLT2 Inhibitors on Renal Outcomes in Patients With Chronic Kidney Disease: A Meta-Analysis Li, Ning Lv, Dan Zhu, Xiangjun Wei, Ping Gui, Yuan Liu, Shijia Zhou, Enchao Zheng, Min Zhou, Dong Zhang, Lu Front Med (Lausanne) Medicine Introduction: The effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors on renal outcomes in patients with chronic kidney disease (CKD) were initially demonstrated in recent trials. However, the magnitude of renal benefits for CKD patients with different baseline features and underlying diseases remains unclear. Method: We systematically searched the Embase, PubMed, Web of Science, and Cochrane library databases from inception to April 15, 2021 to identify eligible trials. The primary outcome was a composite of worsening kidney function, end-stage kidney disease (ESKD), or renal death. Efficacy and safety outcomes were stratified by baseline features, such as type 2 diabetes, heart failure, atherosclerotic cardiovascular disease, proteinuria, and renal function. Results: A total of nine studies were included. These studies included 25,749 patients with estimated glomerular filtration rate (eGFR)<60 mL/min/1.73 m(2) and 12,863 patients with urine albumin-to-creatinine ratio (UACR) >300 mg/g. SGLT2 inhibitors reduced the risk of the primary renal outcome by 30% in patients with eGFR<60 mL/min/1.73 m(2) (HR 0.70, [95% CI 0.58–0.83], I(2) = 0.00%) and by 43% in patients with UACR > 300 mg/g (HR 0.57, [95% CI 0.48–0.67], I(2) = 16.59%). A similar benefit was observed in CKD patients with type 2 diabetes. SGLT2 inhibitors had no clear effects on renal outcomes in patients with eGFR<60 mL/min/1.73 m(2) combined with atherosclerotic cardiovascular disease (HR 0.74, [95% CI 0.51–1.06], I(2) = 0.00%). However, they reduced the risk of major renal outcomes by 46% (HR 0.54, [95% CI 0.38–0.76], I(2) = 0.00%) in patients with atherosclerotic cardiovascular disease and macroalbuminuria (defined as UACR > 300 mg/g). SGLT2 inhibitors did not significantly reduce the risk of major renal outcomes in CKD patients with heart failure (eGFR<60 mL/min/1.73 m(2): HR 0.81, [95% CI 0.47–1.38], I(2) = 0.00%; UACR > 300 mg/g: HR 0.66, [95% CI 0.41–1.07], I(2) = 0.00%). SGLT2 inhibitors showed consistent renal benefits across different levels of eGFR (P interaction = 0.48). Conclusion: SGLT2 inhibitors significantly reduced the risk of the primary outcome in CKD patients. However, for patients with different features and underlying diseases, there exists differences in the renal protective effect. Frontiers Media S.A. 2021-11-01 /pmc/articles/PMC8591237/ /pubmed/34790672 http://dx.doi.org/10.3389/fmed.2021.728089 Text en Copyright © 2021 Li, Lv, Zhu, Wei, Gui, Liu, Zhou, Zheng, Zhou and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Li, Ning
Lv, Dan
Zhu, Xiangjun
Wei, Ping
Gui, Yuan
Liu, Shijia
Zhou, Enchao
Zheng, Min
Zhou, Dong
Zhang, Lu
Effects of SGLT2 Inhibitors on Renal Outcomes in Patients With Chronic Kidney Disease: A Meta-Analysis
title Effects of SGLT2 Inhibitors on Renal Outcomes in Patients With Chronic Kidney Disease: A Meta-Analysis
title_full Effects of SGLT2 Inhibitors on Renal Outcomes in Patients With Chronic Kidney Disease: A Meta-Analysis
title_fullStr Effects of SGLT2 Inhibitors on Renal Outcomes in Patients With Chronic Kidney Disease: A Meta-Analysis
title_full_unstemmed Effects of SGLT2 Inhibitors on Renal Outcomes in Patients With Chronic Kidney Disease: A Meta-Analysis
title_short Effects of SGLT2 Inhibitors on Renal Outcomes in Patients With Chronic Kidney Disease: A Meta-Analysis
title_sort effects of sglt2 inhibitors on renal outcomes in patients with chronic kidney disease: a meta-analysis
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591237/
https://www.ncbi.nlm.nih.gov/pubmed/34790672
http://dx.doi.org/10.3389/fmed.2021.728089
work_keys_str_mv AT lining effectsofsglt2inhibitorsonrenaloutcomesinpatientswithchronickidneydiseaseametaanalysis
AT lvdan effectsofsglt2inhibitorsonrenaloutcomesinpatientswithchronickidneydiseaseametaanalysis
AT zhuxiangjun effectsofsglt2inhibitorsonrenaloutcomesinpatientswithchronickidneydiseaseametaanalysis
AT weiping effectsofsglt2inhibitorsonrenaloutcomesinpatientswithchronickidneydiseaseametaanalysis
AT guiyuan effectsofsglt2inhibitorsonrenaloutcomesinpatientswithchronickidneydiseaseametaanalysis
AT liushijia effectsofsglt2inhibitorsonrenaloutcomesinpatientswithchronickidneydiseaseametaanalysis
AT zhouenchao effectsofsglt2inhibitorsonrenaloutcomesinpatientswithchronickidneydiseaseametaanalysis
AT zhengmin effectsofsglt2inhibitorsonrenaloutcomesinpatientswithchronickidneydiseaseametaanalysis
AT zhoudong effectsofsglt2inhibitorsonrenaloutcomesinpatientswithchronickidneydiseaseametaanalysis
AT zhanglu effectsofsglt2inhibitorsonrenaloutcomesinpatientswithchronickidneydiseaseametaanalysis